Niki BioSolutions: appoints chief financial officer

What happened The filing reports that on Oct 9, 2026 the board appointed Thomas Freeburg as chief financial officer. The appointment is for a two-year term and commenced Sep 1, 2026, and Mr. Freeburg will serve at the discretion of the board.

Key details

• Compensation: base salary of $250,000, with $25,000 deferred until the company receives certain funding; base salary will increase to $275,000 upon the company’s receipt of additional funding; eligible for an annual bonus up to 50% of base salary.
• Equity: 50,000 stock options with an exercise price of $8.83 per share and an agreed vesting schedule.
• Term and termination: two-year term; either party may terminate with 45 days’ notice prior to the end of the then current term; company may remove Mr. Freeburg at any time for cause; the agreement specifies benefits and severance based on the reason for termination.
• Background and disclosures: Mr. Freeburg, age 59, is a Certified Public Accountant with prior roles at Interpace Biosciences, Coach, Inc., Scholastic Corporation and Cambridge Accounting Group; the filing states there are no family relationships or reportable transactions under Item 404(a) of Regulation S-K.

Why it may matter This report is Item 5.02 (departure of directors or certain officers) and covers the appointment of an officer and the material terms of his employment agreement. This filing does not show why the insider traded or why the company acted.